Insufficient scRNA-seq data for expression of CYP2R1 at single-cell level.
Insufficient scRNA-seq data for expression of CYP2R1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 100% | 1271.05 | 245 / 245 | 100% | 10.75 | 501 / 502 |
| breast | 100% | 916.33 | 459 / 459 | 100% | 11.88 | 1115 / 1118 |
| pancreas | 100% | 925.66 | 328 / 328 | 99% | 8.59 | 177 / 178 |
| intestine | 100% | 1175.77 | 966 / 966 | 99% | 10.21 | 522 / 527 |
| lung | 99% | 973.40 | 575 / 578 | 99% | 9.71 | 1148 / 1155 |
| bladder | 100% | 979.33 | 21 / 21 | 99% | 9.32 | 497 / 504 |
| esophagus | 100% | 1004.74 | 1445 / 1445 | 98% | 11.14 | 180 / 183 |
| stomach | 100% | 1236.64 | 359 / 359 | 98% | 9.78 | 281 / 286 |
| kidney | 100% | 685.96 | 89 / 89 | 98% | 6.94 | 883 / 901 |
| thymus | 100% | 787.95 | 653 / 653 | 98% | 6.47 | 591 / 605 |
| liver | 99% | 529.12 | 224 / 226 | 99% | 7.04 | 400 / 406 |
| ovary | 100% | 625.42 | 180 / 180 | 97% | 6.51 | 416 / 430 |
| skin | 100% | 1330.57 | 1809 / 1809 | 96% | 7.02 | 452 / 472 |
| brain | 96% | 490.86 | 2530 / 2642 | 99% | 6.56 | 699 / 705 |
| uterus | 100% | 797.07 | 170 / 170 | 94% | 9.00 | 430 / 459 |
| adrenal gland | 99% | 629.27 | 256 / 258 | 93% | 6.30 | 214 / 230 |
| adipose | 100% | 755.86 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| spleen | 100% | 1370.61 | 241 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 6.99 | 1 / 1 |
| blood vessel | 99% | 818.70 | 1328 / 1335 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 98% | 8.25 | 44 / 45 |
| lymph node | 0% | 0 | 0 / 0 | 97% | 9.22 | 28 / 29 |
| heart | 95% | 461.38 | 819 / 861 | 0% | 0 | 0 / 0 |
| muscle | 89% | 297.66 | 714 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 78% | 438.33 | 726 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 78% | 4.06 | 62 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006805 | Biological process | xenobiotic metabolic process |
| GO_0006766 | Biological process | vitamin metabolic process |
| GO_0006082 | Biological process | organic acid metabolic process |
| GO_0036378 | Biological process | calcitriol biosynthetic process from calciol |
| GO_0010164 | Biological process | response to cesium ion |
| GO_0010212 | Biological process | response to ionizing radiation |
| GO_0042359 | Biological process | vitamin D metabolic process |
| GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_1902271 | Molecular function | D3 vitamins binding |
| GO_0042803 | Molecular function | protein homodimerization activity |
| GO_0005506 | Molecular function | iron ion binding |
| GO_0030343 | Molecular function | vitamin D3 25-hydroxylase activity |
| GO_0008395 | Molecular function | steroid hydroxylase activity |
| GO_0020037 | Molecular function | heme binding |
| GO_0016712 | Molecular function | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen |
| Gene name | CYP2R1 |
| Protein name | Cytochrome P450 family 2 subfamily R member 1 Vitamin D 25-hydroxylase (EC 1.14.14.24) (Cytochrome P450 2R1) |
| Synonyms | |
| Description | FUNCTION: A cytochrome P450 monooxygenase involved in activation of vitamin D precursors. Catalyzes hydroxylation at C-25 of both forms of vitamin D, vitamin D(2) and D(3) (calciol) . Can metabolize vitamin D analogs/prodrugs 1alpha-hydroxyvitamin D(2) (doxercalciferol) and 1alpha-hydroxyvitamin D(3) (alfacalcidol) forming 25-hydroxy derivatives . Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) . . |
| Accessions | E9PS56 Q6VVX0 ENST00000525015.1 ENST00000534686.5 ENST00000334636.10 E9PJT9 ENST00000530609.5 ENST00000532805.1 K7EMQ4 ENST00000532378.5 |